

FOI REF: 26/088

20th February 2026

Eastbourne District General Hospital

Kings Drive
Eastbourne
East Sussex
BN21 2UD

Tel: 0300 131 4500

Website: www.esht.nhs.uk

FREEDOM OF INFORMATION ACT

I am responding to your request for information under the Freedom of Information Act. The answers to your specific questions are as follows:

1. Does your Trust treat patients for the two following conditions?

- Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)
- Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)

Yes.

If yes:

1a. How many patients did the Trust treat in calendar year 2025 (January to December) for each of the below conditions?

- | | |
|---------------------------------------|----|
| • Waldenström macroglobulinaemia (WM) | 45 |
| • Marginal zone lymphoma (MZL) | 3 |

1b. Are there any ongoing clinical trials running at the Trust for each of the below conditions? Please can you advise on any details available on the clinical trials.

- Waldenström macroglobulinaemia (WM)
- Marginal zone lymphoma (MZL)

East Sussex Healthcare NHS Trust (ESHT) does not have any clinical trials for either condition.

Please skip 1c to question 2 and 3.

If no:

1c. Which Trust(s) does the Trust refer patients onto for treatment for each of the above conditions?

Not applicable.

2. How many patients (and new patients* if possible) received treatment for Waldenström macroglobulinaemia (WM) in the period 1st July 2025 to 31st December 2025?

Waldenström macroglobulinaemia (WM) (ICD-10 C88.0)		
Regimen	Total Patients	New Patients*
Fludarabine, cyclophosphamide and rituximab (Known as FCR)	0	0
Bendamustine in combination with rituximab (Known as BR)	1	1
Ibrutinib	18	0
Ibrutinib in combination with rituximab	0	0
Zanubrutinib	15	2
Acalabrutinib	0	0
Chemotherapy (Other than the listed regimens)	0	0
Wait and watch - no active treatment and monitoring only	0	0
Any other treatment (Other than the listed regimens)	11	5

* Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

3. How many patients (and new patients* if possible) received treatment for Marginal zone lymphoma (MZL) in the period 1st July 2025 to 31st December 2025?

Marginal zone lymphoma (MZL) (ICD-10 C83.0 & C88.4)		
Regimen	Total Patients	New Patients*
Bendamustine in combination with rituximab (Known as BR)	1	0
Chlorambucil in combination with rituximab (Known as CR)	0	0
R CVP (Rituximab + cyclophosphamide + vincristine + prednisolone)	0	0
R CHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)	0	0
Zanubrutinib	1	0
Stem Cell Transplant - Please refer to page 3.	-	-
Wait and watch - no active treatment and monitoring only	-	-
Any other treatment (Other than the listed regimens)	1	1

* Please define a new patient as a new patient to treatment, receiving the specified treatment for the first time since December 2024.

Please note that ESHT does not treat patients with stem cell transplant. ESHT patients are referred to Kings College Hospital (KCH), therefore please refer this part of your request direct to KCH via the following email address:

kch-tr.foi@nhs.net

If I can be of any further assistance, please do not hesitate to contact me.

Should you be dissatisfied with the Trust's response to your request, you have the right to request an internal review. Please write to the Freedom of Information Department (esh-tr.foi@nhs.net), quoting the above reference, within 40 working days. The Trust is not obliged to accept an internal review after this date.

Should you still be dissatisfied with your FOI request, you have the right of complaint to the Information Commissioner at the following address:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire SK9 5AF

Telephone: 0303 123 1113

Yours sincerely

Freedom of Information Department
esh-tr.foi@nhs.net